蘋果及英特爾率先採用臺積電3納米晶片生產技術
《日經新聞》報道,蘋果(AAPL.US)及英特爾(INTL.US)率先採用臺積電(TSM.US)的新一代3納米晶片工藝來測試自家晶片設計,預計這類晶片將於明年下半年開始進行商業生產。
目前消費產品是採用臺積電的5納米工藝,該技術亦用於所有蘋果iPhone 12的晶片上。據臺積電稱,3納米與5納米相比,運算能力提高10%至15%,同時功耗亦會降低25%至30%。
消息人士稱,蘋果的iPad可能是第一款採用3納米技術的設備,而明年推出的新iPhone則會採用4納米工藝。
英特爾現時正在與臺積電合作展開至少兩個3納米項目,包括爲手提電腦及數據中心伺務器設計中央處理器,預計這些晶片最早於明年開始量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.